Chimeric Therapeutics (ASX:CHM) updates about fourth dose cohort in CHM 1101 study - Kalkine Media

Highlights

• Chimeric Therapeutics’ CHM 1101 (CLTX CAR T) therapy is undergoing trial at the City of Hope
• This cell therapy is being designed to treat glioblastoma by Chimeric, Australia’s leader in cell therapy
• The third dose cohort was completed in January this year without any dose limiting toxicities
• The company has initiated the fourth dose cohort with the first patient receiving dosing

Australia’s Chimeric Therapeutics (ASX: CHM) has announced significant development concerning its CHM 1101 (CLTX CAR T) therapy. The first patient in the fourth dose cohort of the therapy’s ongoing clinical trial has now received dosing. The study is in progress at one of the largest cancer research organisations in the US - the City of Hope’s Cancer Center, which is leading the Phase 1A trial.

Chimeric has said that CLTX CAR T has the potential to meet unmet needs of patients suffering from recurrent or progressive glioblastoma.

The development

The development relates to CLTX CAR T Phase 1 clinical trial being conducted at City of Hope, US. The trial would evaluate the safety and tolerability of the cell therapy. In January 2023, Chimeric had announced the third dose cohort completion. Notably, this completion was done without any dose limiting toxicities.

Now, treatment initiation of first patient in CLTX CAR T fourth dose has been announced, with the patient receiving 440 X 10⁶ cells. This would involve intratumoral and intraventricular administration. Notably, Chimeric Therapeutics has licensed exclusive global rights to IP covering the chlorotoxin (CLTX) CAR-T cells.

In preclinical models, the therapy has exhibited potent antitumor activity against glioblastoma, Chimeric has said. Additionally, the activity was noticed without any off-tumour recognition of normal human cells or tissues. This supports safety and efficacy profile of CLTX CAR T.

The ongoing Phase 1A of clinical trial aims to involve multiple patients with MMP2+ recurrent or progressive glioblastoma.

About Chimeric

The Australian company is focusing on the use of cell therapy for treatment of a range of cancers. Chimeric asserts that these therapies have the potential of curing cancer. In view of this goal, Chimeric is discovering, developing, and commercialising innovative and promising cellular therapies. CHM 1101 (CLTX CAR T), CHM 2101 (CDH17 CAR T), and CHM 0201 (CORE-NK platform) are being studied by Chimeric to achieve the goal.

Share price performance

CHM shares traded at AU$0.070 in the early hours of 06 March 2023. The market capitalisation stood at AU$30.59 million.